Sir,

In April 2019 issue of the *Indian Journal of Ophthalmology*, Rao *et al*.\[[@ref1]\] reported a case of primary orbital low-grade fibromyxoid sarcoma (LGFS), classified by the World Health Organization as a malignant fibroblastic/myofibroblastic neoplasm, in an Indian patient. The authors described the clinical picture, imaging findings, histopathologic and immunohistochemical studies, and the radiotherapy plan. I assume that the aggressive nature and rarity of that tumor to primarily affect an unusual site must trigger the authors to take into consideration weak immune status in the studied patient. Among states associated with weak immunity, infection with human immunodeficiency virus (HIV) has the leading priority. Due to low immunity, co-infection with oncogenic viruses, and life extension due to the antiretroviral therapy, individuals with HIV infection tend to have various forms of tumors in comparison with immunocompetent individuals.\[[@ref2]\] Indeed, myofibroblastic tumor has been reported among HIV-infected patients.\[[@ref3]\] In India, HIV infection is an important health problem. Though no recent data are yet present on the seroprevalence of HIV infection in India, the available data reported the overall HIV seroprevalence of 0.26% compared to a global average of 0.2%.\[[@ref4]\] I assume that HIV infection should be critically considered in the studied patient with LGFS affecting an unusual site. Hence, it was envisaged to conduct the diagnostic algorithm of blood CD4 lymphocyte count and viral overload estimations for HIV infection. If that algorithm was to reveal HIV positivity, the case in question could be regarded a novel case report of HIV-associated primary orbital LGFS in the literature.
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